{"id":"W4409147719","doi":"10.1038/s41408-025-01259-z","title":"Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University","funders":"Cilag; Pharmacyclics; Genentech; National Institutes of Health; National Cancer Institute; University College London; National Institute for Health and Care Research; Ascentage Pharma; SkylineDx; Regeneron Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Celgene; Swedish Orphan Biovitrum; Array BioPharma; Kite Pharma; Gilead Sciences; BeiGene; Sanofi; Amgen; Bristol-Myers Squibb Foundation; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Multiple myeloma; Refractory (planetary science); Progression-free survival; Dosing; Oncology; Surgery; Gastroenterology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005849581,0.0005457852,0.0007331892,0.0002889131,0.0003240226,0.0008558623,0.0004516601,0.0005896459,0.0009446015],"category_scores_gemma":[0.004028527,0.0001997377,0.0007356675,0.0005191576,0.0005847223,0.0004807658,0.0003441541,0.0007124015,0.0003831592],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007548281,"about_ca_system_score_gemma":0.0006487042,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007400919,"about_ca_topic_score_gemma":0.0006071094,"domain_scores_codex":[0.9980695,0.001370693,0.000113671,0.0001793756,0.00016892,0.00009796604],"domain_scores_gemma":[0.9962363,0.0007800353,0.001488371,0.0005867851,0.0003006893,0.0006077694],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2715406,0.01898957,0.51337,0.0008837934,0.003867667,0.001144831,0.001108487,0.004813584,0.01555609,0.000344503,0.003540433,0.1648404],"study_design_scores_gemma":[0.0491391,0.2579245,0.6617305,0.0001434935,0.003364609,0.002102335,0.0004766863,0.00358114,0.007562137,0.0002245038,0.01362006,0.0001308825],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966697,0.00119009,0.0003381147,0.0001360699,0.00001600102,0.0002567638,0.0006871329,0.00002009051,0.0006860512],"genre_scores_gemma":[0.9969211,0.0004956757,0.0005611834,0.0002570633,0.00007204188,0.0002557739,0.001277011,0.000007383528,0.000152812],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005849581,"threshold_uncertainty_score":0.03093594,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08100113878727644,"score_gpt":0.4097567351272792,"score_spread":0.3287555963400027,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}